300 related articles for article (PubMed ID: 32797372)
21. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.
Yamamura T; Araki M; Fujihara K; Okuno T; Misu T; Guo YC; Hemingway C; Matsushima J; Sugaya N; Yamashita M; von Büdingen HC; Miyamoto K
Mult Scler Relat Disord; 2022 May; 61():103772. PubMed ID: 35537314
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
Romeo AR
Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
[TBL] [Abstract][Full Text] [Related]
23. Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Frampton JE
Drugs; 2020 May; 80(7):719-727. PubMed ID: 32266705
[TBL] [Abstract][Full Text] [Related]
24. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.
Lotan I; McGowan R; Levy M
Curr Neuropharmacol; 2021; 19(2):220-232. PubMed ID: 32348222
[TBL] [Abstract][Full Text] [Related]
25. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
Kleiter I; Traboulsee A; Palace J; Yamamura T; Fujihara K; Saiz A; Javed A; Mayes D; Büdingen HV; Klingelschmitt G; Stokmaier D; Bennett JL
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724181
[TBL] [Abstract][Full Text] [Related]
26. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
[TBL] [Abstract][Full Text] [Related]
27. Emerging drugs for the treatment of neuromyelitis optica.
Duchow A; Chien C; Paul F; Bellmann-Strobl J
Expert Opin Emerg Drugs; 2020 Sep; 25(3):285-297. PubMed ID: 32731771
[TBL] [Abstract][Full Text] [Related]
28. Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder.
Magro G
Mult Scler Relat Disord; 2022 Sep; 65():104037. PubMed ID: 35835028
[TBL] [Abstract][Full Text] [Related]
29. Inebilizumab-cdon: USFDA Approved for the Treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder).
Ali F; Sharma K; Anjum V; Ali A
Curr Drug Discov Technol; 2022; 19(1):e140122193419. PubMed ID: 34011260
[TBL] [Abstract][Full Text] [Related]
30. Blockade of IL-6 signaling in neuromyelitis optica.
Araki M
Neurochem Int; 2019 Nov; 130():104315. PubMed ID: 30342072
[TBL] [Abstract][Full Text] [Related]
31. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
Illés Z
Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
[TBL] [Abstract][Full Text] [Related]
32. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Paul F; Marignier R; Palace J; Arrambide G; Asgari N; Bennett JL; Cree BAC; De Sèze J; Fujihara K; Kim HJ; Hornby R; Huda S; Kissani N; Kleiter I; Kuwabara S; Lana-Peixoto M; Law L; Leite MI; Pandit L; Pittock SJ; Quan C; Ramanathan S; Rotstein D; Saiz A; Sato DK; Vaknin-Dembinsky A
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37258412
[TBL] [Abstract][Full Text] [Related]
33. Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder.
Magro G
Clin Immunol; 2022 Aug; 241():109072. PubMed ID: 35798242
[TBL] [Abstract][Full Text] [Related]
34. Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab.
Fujita R; Aratake Y; Nakata K; Fujii C; Kondo T
Intern Med; 2023 Nov; 62(22):3317-3320. PubMed ID: 37032080
[TBL] [Abstract][Full Text] [Related]
35. Eculizumab in the treatment of neuromyelitis optica spectrum disorder.
Giglhuber K; Berthele A
Immunotherapy; 2020 Oct; 12(14):1053-1066. PubMed ID: 32772617
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
[TBL] [Abstract][Full Text] [Related]
37. [Neuromyelitis Optica Spectrum Disorders - Present Insights and Recent Developments].
Lohmann L; Klotz L; Wiendl H
Fortschr Neurol Psychiatr; 2021 Oct; 89(10):516-530. PubMed ID: 34666391
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
[TBL] [Abstract][Full Text] [Related]
39. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
Yamamura T; Weinshenker B; Yeaman MR; De Seze J; Patti F; Lobo P; von Büdingen HC; Kou X; Weber K; Greenberg B
Mult Scler Relat Disord; 2022 Oct; 66():104025. PubMed ID: 36007339
[TBL] [Abstract][Full Text] [Related]
40. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases.
Mader S; Kümpfel T; Meinl E
Curr Opin Neurol; 2020 Jun; 33(3):362-371. PubMed ID: 32304439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]